INTRODUCTION
Hypertension is one of the leading public health problems in both developed and developing countries. Studies have shown that cardiovascular morbidity and mortality are closely related to systolic and diastolic blood pressure. Up-to-date guidelines are needed in order to achieve the targets that have been accepted as international standards for diagnosing and treating hypertension. Although the guidelines are not decisive in themselves alone, they assist physicians in the approach that they take towards hypertension. 1 In 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) released new guidelines for prevention, detection, evaluation and management of hypertension in adults. The new guidelines lower the threshold for the diagnosis of hypertension and target blood pressure levels of 130/80 mmHg in the general population. The new classification will add a large number of patients who will now be diagnosed as hypertensive, whose blood pressure was previously considered to be within the normal range. 2 The 2017 ACC/AHA guidelines differ from the criteria of the Eighth Joint National Committee (JNC-8) report, which was published in 2014. 3 The new guidelines have developed a more aggressive approach that can be summarized as three main strands: (1) The threshold for defining hypertension has been decreased from 140/90 mmHg to 130/80 mmHg; (2) Independent of cardiovascular risk factors and blood pressure levels, the blood pressure target value has been set to < 130/80 mmHg; and (3) Selection of two antihypertensive drugs for patients with a blood pressure of 140/90 mmHg and over has been adopted (which comprises stage 2 hypertension according to the 2017 ACC/AHA guidelines, or stage 1 hypertension according to other guidelines). 4 The new guidelines emphasize that cardiovascular disease, diabetes or a risk of more than 10% of developing cardiovascular disease within 10 years, are as important as the blood pressure values in treating hypertension. Other points of particular interest in the new guidelines are the importance placed on home blood pressure measurement and teamwork in hypertension management. 5 Unlike the 2017 ACC/AHA guidelines, the 2013 guidelines of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) defined the threshold for stage 1 hypertension and for starting pharmacological treatment as 140-159 mmHg of systolic blood pressure (SBP) or 90-99 mmHg of diastolic blood pressure (DBP). 6 The 2018 ESH/ESC hypertension guidelines have now also been released and the blood pressure thresholds for classifying hypertension remain the same as in the previous European guidelines. 7 Threshold values for identifying and classifying the diagnosis of hypertension, and for determining the time to start pharmacological treatment, the target values and the treatment strategies, are important for community health and for healthcare costs. In the present study, these two current guidelines, based on different threshold values for diagnosing hypertension and on different classification tables, were evaluated through our sample. In addition, the association between demographic and cardiovascular risk factors and hypertension was examined based on the diagnostic threshold values for hypertension that are accepted in each of the two guidelines.
OBJECTIVE
The objective of this study was to analyze the impact of each threshold, i.e. those accepted by 2017 ACC/AHA guidelines and the 2018 European hypertension guidelines, on patients' diagnoses. In addition, we sought to ascertain the associations between the cardiovascular risk factors and each of the thresholds.
METHODS

Design and setting
This observational cross-sectional study was conducted at Gülhane Educational and Research Hospital, Ankara, Turkey.
Participants, variables and data sources
A total of 437 consecutive patients who had been admitted to the hypertension outpatient clinic with a diagnosis of hypertension at the baseline assessment were recruited for this study.
The baseline SBP/DBP values of this sample, from among all the enrolled patients for whom blood pressures were evaluated between 1990 and 2010, were extracted from the patients' medical files. Patients with mental disorders and malignancies, and those younger than 18 years, were excluded from the study.
After the initial evaluation of inclusion criteria and after excluding patients with deficient laboratory results, a total of 372 participants (85.1%) remained enrolled in the study.
All the study variables including the blood pressure measurement were obtained at the baseline assessment on the patients.
The personal characteristics surveyed included the patients' age group (≤ 45 years versus 46-65 years versus > 60 years), sex, obesity (body mass index, BMI ≥ 30 kg/m 2 versus BMI < 30 kg/m 2 ), smoking status (current smoker versus others) and family history of hypertension (yes versus no). Presence of any of the following diseases was also assessed: coronary artery disease (CAD), both types of diabetes mellitus (DM), dyslipidemia and chronic kidney disease (CKD). Presence of comorbidities was ascertained according to self-reports from the study participants at the baseline evaluation.
The patients' laboratory values were obtained from the hospital's electronic biochemistry data service and from the patients' files.
Ethical considerations
The study protocol was approved by the Institutional Review Board of the Gülhane Education and Research Hospital of Ankara, Turkey (no. 1491-676-10/1539; date: February 19, 2010). This study was conducted in accordance with the principles of the Declaration of Helsinki. The researchers also guaranteed that the participants'
identities and related health records would be kept confidential.
Statistical analysis
The patient groups were categorized according to the thresholds for the diagnosis of hypertension indicated by the two sets of guidelines. The statistical analysis was carried out using the Binary logistic regression modeling was used to examine the association between cardiovascular risk factors and the diagnosis of hypertension based on these two sets of guidelines, while controlling for and including all other variables.
The results were presented as odds ratios (OR) and 95% confidence intervals (95% CI). The data were considered to be statistically significant at P-values < 0.05.
RESULTS
A total of 372 patients with a mean age of 62.36 ± 11.45 years (range: 25-88) were enrolled in this study. Just over three-fourths (76.3%; n = 284) of the study participants were female. Among all the patients, 43.3% (n = 161) were in the age group > 65 years, while 48.7% (n = 181) were in the age group 46-65 years. Only a small proportion of the patients (14%) were smoking currently.
Other cardiovascular risk factors and comorbid diseases are shown in Table 1 .
In the whole study group, 74.5% (n = 277) of the patients were number of patients presenting this in the group with hypertension (11.2%, n = 31) was significantly lower than the number of patients with osteoporosis in the group without hypertension (20%, n = 19).
In accordance with the definition of the 2018 ESH/ESC guidelines, comparing the patients who had hypertension with those who did not, although the patients in the hypertension group were older and more frequently presented obesity, no statistically significant difference was detected based on cardiovascular risk factors and comorbidities ( Table 1 ). According to the results from the univariate analysis, there were no significant variables associated with the diagnoses of hypertension that were defined in the 2017 ACC/AHA guidelines ( Table 2) .
The results from the multivariate logistic regression analysis revealed that the significant demographic and cardiovascular risk factors associated with the diagnosis of hypertension according to the 2018 ESH/ESC guidelines were the following: age (OR:
1.027; 95% CI: 1.001-1.054; P = 0.042), obesity (OR: 4.534; 95% CI: 1.830-11.237; P = 0.001) and family history of hypertension (OR: 2.199; 95% CI: 1.252-3.862; P = 0.006). According to the regression analysis, no significant difference was detected in terms of the association between cardiovascular risk factors and the diagnosis of hypertension according to the 2017 ACC/AHA guidelines ( Table 3) .
DISCUSSION
It has been predicted that, through lowering the threshold for making the diagnosis of hypertension to 130/80 mmHg, the 2017 ACC/AHA guidelines will increase the number of patients who will be diagnosed with hypertension and need treatment. in relation to antihypertensive drug treatment. 8, 9 According to this meta-analysis in The Lancet, a reduction of about 25% in blood pressure was effective in preventing the development of cardiovascular events in patients with SBP of 130 mmHg and above.
However, even though SPRINT is a well-organized study, some notable concerns remain when its results are adapted for use in guidelines or real-life daily practice. The beneficial results shown by studies that have early termination may sometimes be greater than should be expected. 8 The difference between the 2017 ACC/AHA guidelines and the previous guidelines means that the number of hypertensive patients in the United States is expected to increase from 32% to 46%, simply through changing the definition of hypertension.
Moreover, the target blood pressure has decreased along with the lowering of the diagnostic threshold. According to the authors of the 2017 ACC/AHA guidelines, the prevalence of hypertension was expected to increase significantly through these guidelines. However, they claimed that early diagnosing of cardiovascular events may become possible and awareness of hypertension among patients at risk will increase over the course of these individuals' future lives. 10 In addition to hypertension, conditions of accompanying cardiovascular disease or diabetes, or 10-year risk of developing cardiovascular disease greater than 10%, should be taken into consideration in the management of antihypertensive treatment. The latest (2017) ACC/AHA guidelines have emphasized the importance of home blood pressure monitoring and teamwork in the management of disease. 10 The authors of these new guidelines claimed that, since drug treatment is recommended especially in cases of clinical cardiovascular diseases such as CAD, coronary heart disease (CHD) and stroke, or in cases with a risk of developing cardiovascular disease greater than 10%, in patients with stage 1
blood pressure values (130-139/80-89 mmHg), the new classification will not increase antihypertensive drug use. 2 However, other physicians have contested this assumption. 11 The new blood pressure classification proposed in the 2017 ACC/AHA guidelines has been adapted to hypertension studies in different countries. Application of the threshold value of 130/80 mmHg to the latest national Chinese research data showed that the hypertension rate rose from 25% to 50%. The proportion of patients requiring medication in the Chinese population was 2.0% in the general population and 5.5% in the geriatric patient population according to the 2017 ACC/AHA guidelines. 12 Based on the threshold of ≥ 140/90 mmHg, the current prevalence of hypertension in India is approximately 28.9% in both men and women. In the Indian population, in which there are interactions with various social, cultural and economic factors, hypertension management has become quite difficult with the lower blood pressure values that have redefined hypertension in the new 2017 ACC/AHA guidelines. 13 It seems to be taking time in India for implementation of another emphasis of the 2017 ACC/ AHA guidelines, i.e. widespread adoption of out-of-office blood pressure measurement, across the country. The current situation in which the vast majority of the cost of medicines in India purchased through personal budgets is refunded also increases concern about the increased risk of antihypertensive drug usage. 15 In a study involving 6106 adults randomized from rural areas of India, a 14% increase in the number of stage 1 hypertension patients was observed, with re-evaluation of 2815 individuals according to the new thresholds. 14, 16 Another factor affecting the international generalizability of the new guidelines, which basically arose from the SPRINT study data, is blood pressure differences based on ethnicity disparities between countries. Since the proportion of East Asian ethnicity in the SPRINT trial was very low (< 2%), it is doubtful whether the results can be generalized to countries like Taiwan. 4 In our study, the patients who enrolled at the hypertension outpatient clinic were evaluated regarding blood pressure thresh- Our study conducted in Turkey can be considered to be a pilot reflecting the thresholds of the new 2017 ACC/AHA guidelines in our society. However, these increased rates of hypertension cannot be generalized to the entire Turkish population because our study had some limitations, including its small sample size and the structure of the outpatient clinic studied, which only serves hypertensive patients. Furthermore, the number of female patients evaluated was higher than the number of male patients.
CONCLUSIONS
The decreases in hypertension threshold values proposed through the 2017 ACC/AHA guidelines have increased the number of patients diagnosed with hypertension worldwide, including in Turkey. This increase was by 16.6 percentage points in our sample.
We consider that updates to the relationship between cardiovascular risk factors and the diagnosis of hypertension through the change in threshold values may come to be presented in the near future, consequent to ongoing studies in various countries
worldwide. In the current study, age, obesity and family history of hypertension were significantly associated with the diagnosis of hypertension according to the 2018 ESC guidelines, while no relationship was detected between cardiovascular risk factors and the diagnosis of hypertension using the 2017 ACC guidelines.
Studies involving higher numbers of patient samples will be effective in explaining the relationship between these risk factors and the diagnosis of hypertension.
